Theseus Pharmaceuticals announces the price of its IPO
CAMBRIDGE, Mass., October 6, 2021 / PRNewswire / – Theseus Pharmaceuticals, Inc. (“Theseus”), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, announced today hui the price of its initial public offering of 10,000,200 shares of its ordinary shares at a public price of $ 16.00 per share. All shares are offered by Theseus. The gross proceeds of the Offering for Theseus, before deduction of any subscription discounts, commissions and other offering charges payable by Theseus, are expected to be $ 160 million. In addition, Theseus has granted the underwriters a 30 day option to purchase up to 1,500,030 additional common shares of Theseus at the initial public offering price less discounts and subscription fees.
Theseus common stock is expected to begin trading on the Nasdaq Global Select Market under the symbol “THRX” on October 7, 2021. The offer is expected to close on or around October 12, 2021, subject to the satisfaction of the closing conditions usual.
Jefferies, SVB Leerink and Cantor act as co-managers of the offer. Wedbush PacGrow acts as a leader.
A registration statement relating to the securities sold under the Offer was declared effective by the Securities and Exchange Commission (“SEC”) on October 6, 2021. The Offer is being made only by means of a written prospectus. Copies of these documents can be viewed by visiting the SEC website at http://www.sec.gov. Alternatively, copies of the final prospectus relating to the offering can be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York State 10022, by phone at (877) 821-7388, or by email at [email protected]; SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by phone at (800) 808-7525, ext. 6105, or by email at [email protected]; Cantor Fitzgerald & Co., Attention Capital Markets, 499 Park Avenue, 4th Floor, New York, New York State 10022, or by e-mail to [email protected].
This press release does not constitute an offer to sell or the solicitation of an offer to buy such securities, and there will be no sale of such securities in any state or jurisdiction in which such an offer, solicitation or sale would be illegal prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Theseus Pharmaceuticals, Inc.
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of targeted transformative therapies. Theseus is developing next-generation tyrosine kinase (TKI) inhibitors: targeted “pan-variant” therapies that treat all major mutations in drug resistance. Theseus’ flagship product candidate THE-630 is a panvariant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GISTs), whose cancer has developed resistance to first-line kinase inhibitor therapy . Theseus is also developing a fourth generation selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first-line or subsequent-line osimertinib therapy in patients with non-small-scale lung cancer. cells (NSCLC).
SOURCE Pharmaceutical Thesis